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Thrombospondin (TSP) is a 450-kDa extracellular matrix glycoprotein which supports the growth of human MG-63 osteoblastic ells [Abbadia 
et al., FEBS Lett., 329 (1993) 341-3461. In this study, we describe the effect of the glucocorticoid, dexamethasone, on cell proliferation and TSP 
expression by MG-63 cells. Using a serum-free mitogenesis assay, dexamethasone (25 to 500 nM) caused a dose-dependent decrease in [3H]thymidine 
incorporation by MG-63 eels in culture, reaching 40% inhibition of cell proliferation at a concentration of 250 nM. Similarly, the stimulatory effect 
of TSP (500 t&ml) on proliferation of MG-63 cells was totally abolished in the presence of dexamethasone (250 nM). In situ hybridization indicated 
that TSP mRNA level in dexamethasone-treated MG-63 cells decreased compared to quiescent cells. As judged by fluorescence-activated cell sorting 
analysis, dexamethasone treatment of MG-63 cells resulted in a 50 to 70% decrease in TSP cell surface expression compared to quiescent cells. 
Secretion of TSP in the culture fluid of dexamethasone-treated MG-63 cells also decreased by 40% while, under similar experimental conditions, 
a 180% increase in alkaline phosphatase activity was observed in dexamethasone-treated c lls. Because glucocorticoids induce osteoporosis in vivo 
and reduce proliferation of osteoblasts in vitro, our results argue for an important role of TSP during bone formation. 
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1. INTRODUCTION 
Thrombospondin (TSP) is a trimeric extracellular 
matrix glycoprotein of 450 kDa synthesized and se- 
creted by a wide range of normal and transformed cells 
[ 11. Recently, five distinct genes encoding for four struc- 
turally different TSPs (TSPl, TSP2, TSP3, and TSP4), 
and cartilage oligomeric matrix protein (COMP) have 
been described [2]. The functions of TSP2, TSP3, TSP4, 
and COMP are unknown. TSPl has been described as 
a protein that modulates cellular proliferation. In situ, 
there is a precise regional and temporal appearance of 
TSP during organogenesis of mouse embryo, followed 
by a disappearance as differentiation proceeds [3]. In 
vitro, TSP promotes proliferation of fibroblasts and 
facilitates growth of smooth muscle cells in response to 
EGF [I]. In addition, exposure of smooth muscle cells 
to anti-TSP antibodies causes decreased proliferation 
[l]. TSP has been identified in the mineralized bone 
matrix of neonatal and young (growing) bone of many 
animal species [4], and we have reported that TSP, 
*Corresponding author. Fax: (33) 72 35 05 7. 
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which is synthesized and secreted by human MG-63 
osteoblastic ells in culture [5], promotes the growth of 
these osteoblastic cells through a prostaglandin-medi- 
ated mechanism [6]. Taken together, these findings [ 1,3- 
6] are consistent with an important role for TSP in cell 
proliferation. 
Long-term treatment with glucocorticoids has been 
associated with osteoporosis, which is characterized by 
a decrease in bone mass [7]. Glucocorticoid-induced 
osteoporosis primarily involves decreased width of tra- 
becular bone, suggesting reduction of trabecular os- 
teoblast proliferation [7]. Osteoblastic ells have recep- 
tors for glucocorticoids [8], and cultured mouse 
MC3T3-El osteoblastic cells have been used to show 
that the glucocorticoid, dexamethasone, inhibits DNA 
synthesis and prostaglandin synthesis [9]. In addition, 
glucocorticoids also affect the expression of bone ex- 
tracellular matrix proteins including type I collagen 
[lo], osteocalcin [11,12], alkaline phosphatase [12,13], 
osteopontin [14], bone sialoprotein [15], and fibronectin 
[ 161. All of these extracellular matrix proteins undoubt- 
edly play an important role in bone cell morphology, 
and could be contributing factors to the reduced bone 
quality and reduced bone formation seen in glucocorti- 
coid-induced osteoporosis. However, although alkaline 
phosphatase activity is inversely related to cell prolifer- 
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ation [13], none of these extracellular matrix proteins 
have been shown to modulate the growth of osteoblastic 
cells directly. These tidings, taken together with the 
fact that TSP stimulates the growth of human MG-63 
osteoblastic ells [6], prompted us to examine whether 
the glucocorticoid, dexamethasone, could inhibit the 
growth of human osteoblastic cells through inhibition 
of TSP expression. 
2. MATERIALS AND METHODS 
EcoRI, BumHI, [HJthymidine, and [cc-~~S]UTP were purchased 
from Amersham. Proteinase K was from Boehringer. Bovine serum 
albumin (BSA) was purchased from Miles Laboratories Inc. (Elkhart). 
Human a-thrombin was from Fibrindex (Ortho Diagnostic Systems). 
Dexamethasone was from Sigma. Human platelet TSPl was obtained 
from Stago (France). Mouse monoclonal antibody PlO and a rabbit 
polyclonal antibody directed against human blood platelet TSPl have 
been described earlier [5,171. Mouse monoclonal antibody MARK 1 
directed against rat IC light chains was purchased from Immunotech 
(France). Goat anti-(mouse IgG) and goat anti-(rabbit IgG) conju- 
gated with fluoroscein isothiocyanate were from Coulter Immunology 
(France). 
The human osteosarcoma cell line designated MG 63 was obtained 
from the American Type Culture Collection (Rockville, MD). MG 63 
cells were cultured in RPM1 1640 medium containing 10% (v/v) fetal 
calf serum. 
For in situ hybridization, cells resuspended in RPM1 medium con- 
taining 10% (v/v) fetal calf serum were plated at a density of 3,000 cells 
per cm* in glass chamber slides (Lab Tee) and allowed to attach 
overnight in a 5% COz incubator at 37’C. After incubation, cells were 
washed and cultured in RPM1 medium containing 1% (mass/vol.) BSA 
for 24 h. Cells were then treated with a-thrombin (0.1 U/ml) or dexa- 
methasone (250 nM) for 48 h. After washing, cells were hxed for 
15 min in PBS containing 2% (m/v) paraformaldehyde, washed twice 
in PBS, dehydrated by immersion in ethyl alcohol, and air dried. Cells 
were then pretreated for 5 mitt with PBS containing 5 mM MgCl,, then 
incubated for 8 min with 5 @ml proteinase K (in PBS), rinsed twice 
in PBS and dehydrated in ethyl alcohol. Hybridization with the RNA 
probes, and the subsequent steps of the procedure have b en detailed 
previously [6]. 
Cell surface expression of TSP by MG-63 cells stimulated or not 
with dexamethasone (250 nM) was studied on a FACS flow cytometer 
(Be&on Dickinson) using either anti-TSP antibodies or negative con- 
trol antibody MARK 1 as the primary antibody, and fluoroscein 
isothiocyanate-conjugated IgGs as the secondary antibody. The ex- 
perimental procedure was essentially as previously described [18]. 
Quantitation of TSP secreted by MG-63 osteoblastic ells was per- 
formed by enzyme-linked immunosorbent assay (ELISA). Cells resus- 
pended in RPM1 medium containing 10% (v/v) fetal calf serum were 
plated at a density of 13,000 cells/cm2 in 6-well plates, and were grown 
to subconfluence in a 5% CO, incubator at 37°C. The monolayer was 
washed twice with serum-free RPM1 medium to remove any residual 
serum components, and cells were cultured in RPM1 medium contain- 
ing 1% (masslvol) BSA. After 24-h incubation at 37°C cells were 
treated with increasing concentrations of dexamethasone (25 to 500 
nM). Supematants were removed at 48 h after the addition of serum- 
free medium supplemented with BSA. Cell numbers were determined 
using a hemocytometer. Supematants were aliquoted and stored at 
-2O’C prior to assay. TSP present in the supematants was quantified 
using a double-antibody sandwich assay (Stago, France). 
For cell proliferation, MG-63 cells resuspended in RPM1 medium 
containing 10% (v/v) fetal calf serum were plated at a density of 5,000 
cells/well in 96-well flat-bottom culture dishes. After 24-h incubation 
in a 5% CO* incubator at 37’C, cells were washed and cultured in 
RPM1 medium containing 1% (m/v) BSA to make cells quiescent. 
After 24-h incubation, quiescent cells were treated for 48 h with in- 
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creasing concentrations of dexamethasone (25 to 500 nM) in the pres- 
ence or absence of TSP (500 @ml). During the last 12 h of the 48-h 
incubation period, cells were pulsed with 1 &i of [3H]thymidine/well. 
At the end of the incubation, cells were washed three times with PBS 
and harvested after brief exposure to trypsin (0.5 mg/ml) and EDTA 
(0.5 mM). TrypsinlEDTA-treated cells were then resuspended and 
counted. Results obtained for each concentration of dexamethasone 
were the mean f SD. of quadruplicate determinations. 
Assays for alkaline phosphatase activity utilized a 0.016 Mp-nitro- 
phenyl phosphate substrate in 0.9 mM 2-amino-2-methyl-l propanol 
buffer, pH 10.5, containing 1 mM MgCl, (alkaline phosphatase kit, 
Boehringer), and spectrophotometric measurement of reaction prod- 
uct at 405 mn. Untreated cells and cells treated with dexamethasone 
(250 nM) and/or TSP (500 @ml) were harvested after exposure to 
trypsin (0.05 mg/ml) and EDTA (0.5 mM). TrypsimEDTA-treated 
cells were counted and solubiiid in 0.05% Triton X-100 at 4°C for 
30 min. After centrifugation to remove cellular debris, the activity of 
alkaline phosphatase was assayed in solubilized cells. 
3. RESULTS 
3.1. Cell proliferation 
It has been shown that treatment of osteoblastic ells 
with dexamethasone r duced cell proliferation by 40 to 
50%, depending on the cell lines used [9,13]. Experi- 
ments conducted with human MG-63 osteoblastic ells 
showed that dexamethasone induced a significant, dose- 
dependent decrease in [3H]thymidine incorporation by 
these cells, reaching a maximum inhibitory effect (40%) 
at concentrations between 250 and 500 nM (Fig. 1). 
Because TSP induces proliferation of MG-63 osteoblas- 
tic cells at an optimal concentration of 500 ng/ml[6], cell 
proliferation assays were also performed with TSP (500 
ng/ml) in the presence of increasing concentrations (25 
to 500 nM) of dexamethasone (Fig. 2). TSP (500 ng/rnl) 
alone induced a 760 + 129% increase in [3H]thymidine 
incorporation by MG-63 cells when compared to un- 
treated cells (Fig. 2A vs. 2F). By contrast, dexa- 
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Fig. 1. Effect of increasing concentrations of dexamethasone on prolif- 
eration of human MG-63 osteoblastic ells. Data were obtained as 
cpm t3H]thymidine incorporated by dexamethasone-treated c lls and 
normalized as a percentage of the mean cpm incorporated by un- 
treated cells. Results are the mean f S.D. of n experiments. *P G 0.01 
by Mann-Whitney test. 
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Fig. 2. Effect of increasing concentrations of dexamethasone (0 to 500 
nM) on proliferation of human MG-63 osteoblastic ells induced by 
TSP (500 ng/ml). Results were expressed as described in the legend of 
Fig. 1, and are the mean f S.D. of quadruplicate determinations. Two 
independent experiments were carried out with similar results. 
methasone drastically reduced @IJthymidine incorpo- 
ration by TSP-stimulated cells from 760 + 120 to 
98 f 15% of the control value (Fig. 2B-E). 
3.2. In situ hybridization 
With the specific antisense probe, there was high- 
intensity hybridization over quiescent MG-63 osteo- 
blastic cells, while only minimal hybridization was 
observed with the sense probe (Fig. 3A,B). As previ- 
ously reported [6], stimulation of MG-63 cells with a- 
thrombin (0.1 U/ml) caused a drastic increase in TSPl 
mRNA expression (as judged by grain densities) (Fig. 
3C) when compared to tmstimulated cells (Fig. 3A). By 
contrast, treatment of MG-63 cells with dexamethasone 
(250 nM) induced a decrease in TSPl mRNA expres- 
sion (Fig. 3E) when compared to untreated cells (Fig. 
3A). Using the sense probe, nonspecific hybridization 
for thrombin- and dexamethasone-treated MG-63 cells 
(Fig. 3D,F) was to a level similar to that observed for 
their unstimulated counterparts (Fig. 3B). 
3.3. Fluorescence-activated cell sorting analysis 
We have previously observed that TSP expression by 
thrombin-stimulated MG-63 cells is drastically in- 
creased at both mRNA and protein levels using in situ 
hybridization and immunofluorescence, respectively [6]. 
Because of the inhibition of TSP mRNA expression by 
dexamethasone-treated MG-63 cells (Fig. 3), cell sur- 
face expression of TSP was therefore studied by fluores- 
cence-activated cell sorting analysis. Histograms of cell 
number vs. fluorescence intensity showed that the addi- 
tion of an anti-TSP polyclonal antibody to untreated 
MG-63 cells increased the mean fluorescence intensity 
1Cfold when compared to an irrelevant antibody, pro- 
ducing a rightward shift in the histograms (Fig. 4, histo- 
grams c vs. a). Using similar experimental conditions, 
a lo-fold increase in the mean fluorescence intensity was 
observed with anti-TSP monoclonal antibody PlO (re- 
sults not shown). By contrast, addition of an anti-TSP 
polyclonal antibody to dexamethasone-treated MG-63 
cells produced a 70% decrease in fluorescence intensity 
compared to untreated cells (Fig. 4, histograms b vs. c). 
Using similar experimental conditions, a 50% decrease 
in fluorescence intensity was observed with anti-TSP 
monoclonal antibody PlO (results not shown). 
3.4. Enzyme-linked immunosorbent assay 
Secretion of TSP by MG-63 cells increased in a time- 
dependent manner (between 4 and 24 h), reaching a 
plateau at 48 h. Based on comparison with a standard 
curve, the amount of TSP in the culture fluid of the 
MG-63 cells at 48 h was found to be 40 + 4.4 ng/106 cells 
(Fig. 5). Under similar experimental conditions, treat- 
ment of MG-63 cells with increasing concentrations of 
dexamethasone (25 to 500 nM) induced a significant 
dose-dependent inhibition on TSP secretion, reaching a 
maximum inhibitory effect at a concentration of 250 
nM (24 + 2 ng/106 cells; P d 0.01) (Fig. 5). 
3.5. Alkaline phosphatase activity 
Glucocorticoids stimulate alkaline phosphatase ac- 
tivity in a variety of osteoblastic ells [ 12,131. Treatment 
of MG-63 osteoblastic cells with 250 nM dexa- 
methasone led to a 180% increase in alkaline phosphat- 
ase activity when compared to untreated cells (10 + 0.8 
vs. 5.6 + 0.7 U/L/lo6 cells; P Q 0.05) (Fig. 6). For com- 
parison, a 40% decrease in TSP secretion was observed 
with dexamethasone-treated MG-63 cells when com- 
pared to their untreated counterparts (24 + 2 vs. 
40 f 4.4 ng/106 cells; P c 0.01) (Fig. 6). 
4. DISCUSSION 
Glucocorticoid-induced osteoporosis involves reduc- 
tion of osteoblast proliferation [7-9,131, inhibition of 
prostaglandin synthesis [9] and inhibition of the expres- 
sion of bone extracellular matrix proteins including type 
I collagen [lo], osteocalcin [11,12], osteopontin [14], and 
fibronectin [ 163. By contrast, glucocorticoids stimulate 
alkaline phosphatase activity [ 12,131 and bone sialopro- 
tein expression by osteoblastic ells [ 151. Using a super- 
physiological concentration of glucocorticoids (250 nM) 
known to occur in glucocorticoid-treated patients, the 
present study shows that dexamethasone concomi- 
tantly inhibits the expression of TSP and stimulates 
alkaline phosphatase activity in human MG-63 osteo- 
blastic cells. The observation that dexamethasone inhib- 
its TSP expression is based on a number of findings: (a) 
TSP mRNA expression is inhibited in dexamethasone- 
treated MG-63 cells, (b) cell surface expression of TSP 
is decreased by 50 to 70% in the presence of dexa- 
methasone, and (c) secretion of TSP in the culture fluid 
163 
Volume 335, number 2 FEBS LETTERS December 1993 
Fig. 3. Localisation of TSPl mRNA in human MG-63 osteoblastic ells by in situ hybridization. (A) Darkiield photomicrograph of quiescent MG r-63 
cells hybridized with an antisense probe. Note the specilic localization of silver grains over MG-63 cells when compared to the sense probe f :B). 
(C a md D) Darkfield photomicrographs of thrombin-treated ME63 cells hybridized with an antisense probe and a sense probe, respectively. (E 
and F) Darkfield photomicrographs of dexamethasone-treated MG-63 cells hybridized with an antisense probe and a sense probe, respective ely. 
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Fig. 4. Fluorescence-activated cell-sorting analysis of endogenous TSP expressed to the surface of MG-63 osteoblastic ells treated or not with 
dexamethasone. Osteoblastic cells were incubated with an anti-TSP polyclonal antibody or an irrelevant antibody, followed by fluorescein- 
conjugated goat anti-rabbit IgG. Cells were then analysed on a FACScan flow cytometer. Histogram a, binding of an irrelevant antibody to the 
surface of MG-63 cells treated or not with dexamethasone. Histogram b, binding of an anti-TSP polyclonal antibody to the surface of dexa- 
methasone-treated MG-63 cells. Histogram c, binding of an anti-TSP polyclonal antibody to the surface of untreated MG-63 cells. x-axis, fluorescent 
intensity; y-axis, full scale counts. The experiment was carried two times with similar results. 
of dexamethasone-treated MG-63 cells is decreased by 
40%. The observation that dexamethasone stimulates 
alkaline phosphatase activity in human MG-63 osteo- 
blastic cells confirms and extends previous findings ob- 
tained with human trabecular osteoblast-like cells [12] 
and rat ROS 17/2.8 osteoblastic ells [ 131. As previously 
reported for human trabecular osteoblast-like cells 
[ 13,191, the increased activity of this enzyme is inversely 
related to proliferation of human MG-63 cells. Because 
TSP stimulates growth of MG-63 cells [6] and the 
growth-supportive ffect of TSP is inhibited by dexa- 
methasone (this study), it seems therefore that the de- 
creased TSP expression observed in dexamethasone- 
treated MG-63 cells is directly related to the inhibition 
of cell proliferation. The mechanisms by which dexa- 
methasone inhibits both TSP expression and cell growth 
are unknown. Cell surface heparan sulfate proteogly- 
cans serve as a receptor for binding of TSP to many 
kinds of cells in culture [l], including MG-63 cells [20], 
and they also mediate degradation of TSP [21,22]. In 
this regard, dexamethasone could increase endocytosis 
of TSP-proteoglycan complexes, resulting in the de- 
creased TSP cell surface expression seen in dexa- 
methasone-treated MG-63 cells. A down-regulation of 
TSP receptors provides an alternative mechanism by 
which dexamethasone could also inhibit TSP expres- 
sion. For example, TGF# induces a marked decrease 
in adhesion of MG-63 cells to laminin which is related 
to a down-regulation of a@,-integrin [23]. By contrast, 
interleukin-l/I up-regulates a,/&-integrin expression in 
MG-63 cells [24], resulting in cell growth inhibition of 
interleukin-l/I treated MG-63 cells [25]. Besides its ef- 
fect on TSP expression, dexamethasone inhibits growth 
of human MG-63 osteoblastic ells (this study) as has 
been previously reported for cultured mouse osteoblast- 
like cells [8,9]. We have previously suggested that the 
growth-supportive effect of TSP could depend of a 
mechanism whereby cell surface-bound TSP stimulates 
secretion of prostaglandins which, in turn, allow cell 
proliferation to proceed [6]. Dexamethasone inhibits 
prostaglandin synthesis in mouse MC3T3-El osteoblas- 
tic cells and exogenous prostaglandin E, partially re- 
verses growth inhibition induced by the glucocorticoid 
[9]. In this regard, it has been suggested that the inhib- 
itory effect of dexamethasone may be partially mediated 
through a prostaglandin mechanism [9]. The prolifera- 
tive action of prostaglandin E2 in mouse MC3T3-El 
and rat C5.4E osteoblastic cells is mediated through 
40 dn=S 
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Fig. 5. Effect of dexamethasone on secretion of TSP by human MG-63 
osteoblastic ells in culture. MG-63 cells were cultured in RPM1 me- 
dium containing 1% (m/v) bovine serum albumin. After 24-h incuba- 
tion at 37”C, cells were treated with increasing concentration of dex- 
amethasone (O-500 nM) for 48 h at 37°C. TSP was measured in the 
culture supernatants using a double antibody sandwich assay. Results 
are the mean f S.D. of n experiments. *P c 0.01 by Mann-Whitney 
test. 
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Fig. 6. Effect of dexamethasone on alkaline phosphatase activity and 
TSP secretion by human MG-63 osteoblastic ells. Alkaline phosphat- 
ase activity and TSP secretion were measured in the cell layer and the 
culture supematant, respectively. Data values are expressed as percent 
of control from each of 5 experiments. The control value of alkaline 
phosphatase was 5.6 f 0.7 U/l/lo6 cells. The control value of secreted 
TSP was 40 + 4.4 t&O6 cells. Dexamethasone (250 nM) induced a 
180% increase in alkaline phosphatase activity when compared to 
untreated cells (*P s 0.05 by Mann-Whitney test). For comparison, 
a 40% decrease in TSP secretion by MG-63 cells was observed in the 
presence of dexamethasone (*P s 0.01 by Mann-Whitney test). 
activation of protein kinase C [26,27], and it is well 
established that protein kinase C is activated by dia- 
cylglycerol, a second messenger produced by agonists 
of phosphoinositide turnover [28]. Interestingly, submi- 
togenic levels of TSP also stimulate phosphoinositide 
turnover in cultured smooth muscle cells [29]. Based on 
these findings [6,26-291, the growth-supportive ffect of 
TSP may be mediated through protein kinase C activa- 
tion and/or prostaglandin synthesis. It seems therefore 
that at least two different mechanisms could account for 
the reduced cell growth seen in glucocorticoid-treated 
osteoblastic cells: (a) the inhibition of TSP cell surface 
expression by dexamethasone induces a decrease in pro- 
staglandin synthesis which results in reduced cell 
growth and (b) the stimulation of phosphoinositide 
turnover by TSP and/ or prostaglandin Ez is inhibited 
by dexamethasone, leading to the inactivation of pro- 
tein kinase C. In this regard, it will be very interesting 
to investigate whether or not the binding of TSP to cell 
surface heparan sulfate proteoglycans is able to 
transduce intracellular signals, or if other TSP receptors 
are involved in the signal transduction leading to cell 
proliferation. 
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